IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES

被引：0
|
作者：
Ganan-Gomez, I. [1 ]
Alfonso, A. [1 ]
Ogoti, Y. [1 ]
Yang, H. [1 ]
Montalban-Bravo, G. [1 ]
Yu, A. C. [2 ]
Silver, S. [2 ]
Clise-Dwyer, K. [1 ]
Garcia-Manero, G. [1 ]
Colla, S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30165-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
收藏
页码：S34 / S36
页数：3
相关论文
共 50 条
  • [21] DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia
    Flotho, Christian
    Sommer, Sebastian
    Luebbert, Michael
    SEMINARS IN CANCER BIOLOGY, 2018, 51 : 68 - 79
  • [22] Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes
    Venugopal, Sangeetha
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S73 - S76
  • [23] Meta-analysis on hypomethylating agents in myelodysplastic syndromes
    Herbst, Christine
    Baner, Kathrin
    Kreuzer, Karl-Anton
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 342 - 343
  • [24] Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Nelson, Rebecca
    Talati, Chetasi
    Kuykendall, Andrew
    Sweet, Kendra
    Padron, Eric
    Lancet, Jeffrey
    List, Alan
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S339 - S340
  • [25] Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
    Szmigielska-Kaplon, Anna
    Robak, Tadeusz
    CURRENT CANCER DRUG TARGETS, 2011, 11 (07) : 837 - 848
  • [26] Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents
    Loaiza-Bonilla, Arturo
    Gore, Steven D.
    Carraway, Hetty E.
    CURRENT OPINION IN HEMATOLOGY, 2010, 17 (02) : 104 - 109
  • [27] Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
    Finelli, Carlo
    Follo, Matilde Y.
    Stanzani, Marta
    Parisi, Sarah
    Clissa, Cristina
    Mongiorgi, Sara
    Barraco, Marilena
    Cocco, Lucio
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (16) : 2349 - 2357
  • [28] Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : 516 - 523
  • [29] Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes
    Gournay, Viviane
    Robin, Marie
    BULLETIN DU CANCER, 2023, 110 (11) : 1168 - 1175
  • [30] Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
    Pang, Wendy W.
    Pluvinage, John V.
    Price, Elizabeth A.
    Sridhar, Kunju
    Arber, Daniel A.
    Greenberg, Peter L.
    Schrier, Stanley L.
    Park, Christopher Y.
    Weissman, Irving L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (08) : 3011 - 3016
12345